OC
ELDN icon

Oppenheimer & Co’s Eledon Pharmaceuticals ELDN Stock Holding History

Oppenheimer & Co’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-84
Closed -$141K – 1301
2015
Q3 		$141K Buy
84
+10
+14% +$20.6K ﹤0.01% 1227
2015
Q2 		$160K Buy
+74
New +$143K ﹤0.01% 1351

Other funds holding ELDN

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Oppenheimer & Co's ELDN Position: Q4 2015 in Review

Oppenheimer & Co sold out of Eledon Pharmaceuticals (ELDN) in Q4 2015, closing a stake of 84 shares — an estimated $141K sold.

Oppenheimer & Co first reported a position in ELDN in Q2 2015 and held it in 2 quarters. The position peaked at $160K in Q2 2015. 53 funds tracked by Wall St. Rank hold ELDN as of Q4 2015.

  • Oppenheimer & Co reported no remaining Eledon Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 84 Eledon Pharmaceuticals shares in Q4 2015, an estimated $141K.
  • Oppenheimer & Co first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Oppenheimer & Co's Eledon Pharmaceuticals position peaked at $160K in Q2 2015.
  • 53 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2015.

Based on Oppenheimer & Co's 13F filing for Q4 2015, filed 3 Feb 2016.